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Abstract
Background: AURA study reported 61% objective response rate and progression-free survival of 9.6 months with
osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed
this study to describe the experience with osimertinib in Spain.
Methods: Post-authorization, non-interventional Special Use Medication Program, multicenter, retrospective study
in advanced EGFR/T790M+ non-small cell lung cancer. One hundred-fifty five patients were enrolled (August 2016–
December 2018) from 30 sites. Primary objective: progression-free survival. Secondary objectives: toxicity profile,
objective response rate, and use of health service resources.
Results: 70% women, median age 66. 63.9% were non-smokers and 99% had adenocarcinoma. Most patients had
received at least one prior treatment (97%), 91.7% had received previous EGFR-tyrosine kinase inhibitors and 2.8%
osimertinib as first-line treatment. At data cutoff, median follow-up was 11.8 months. One hundred-fifty five patients
were evaluable for response, 1.3% complete response, 40.6% partial response, 31% stable disease and 11.6% disease
progression. Objective response rate was 42%. Median progression-free survival was 9.4 months. Of the 155 patients
who received treatment, 76 (49%) did not reported any adverse event, 51% presented some adverse event, most of
which were grade 1 or 2. The resource cost study indicates early use is warranted.
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Conclusion: This study to assess the real-world clinical impact of osimertinib showed high drug activity in
pretreated advanced EGFR/T790M+ non-small cell lung cancer, with manageable adverse events.
Trial registration: Clinical trial registration number: NCT03790397.
Keywords: Osimertinib, Real-world data, EGFR-activating mutations, T790M EGFR mutation, Second line, Non-small
cell lung cancer
Background
In Spain occur about 27,351 new lung cancer cases per
year and the disease was responsible for 22,896 deaths in
2018 [1, 2]. Most non-small cell lung cancer (NSCLC)
patients are diagnosed with unresectable disease and
around 40% with advanced disease.
The identification of oncogenic driver alterations that
can be targeted by EGFR tyrosine kinase inhibitors
(EGFR-TKI: erlotinib, gefitinib, afatinib, dacotinib) for
EGFR mutated tumors has improved median progression-
free survival (PFS), overall response rates and quality of
life in metastatic NSCLC patients, making EGFR TKIs the
first-line treatment of choice in patients with EGFR muta-
tion (EGFRm) advanced NSCLC [3]. Unfortunately, how-
ever, even these patients eventually develop resistance.
Multiple resistance mechanisms have been observed,
including the EGFR Thr790Met (T790M) resistance mu-
tation, MET amplification, HER2 amplification and small-
cell histological transformation, among others. EGFR
T790M mutations have been detected in 48–62% of pa-
tients that develop resistance to EGFR-TKIs [4, 5].
Until recently, treatment options in the post-EGFR-TKI
second-line setting were limited, with low rates of re-
sponse to platinum-based doublet chemotherapies [6–8].
Osimertinib (AZD9291) is a potent oral irreversible
EGFR-TKI that is selective for both EGFR and T790M
resistance mutations with activity in the central nervous
system (CNS) [9, 10]. In the phase 1 component of the
phase 1/2 AURA trial (ClinicalTrials.gov number,
NCT01802632), objective response rate (ORR) for osi-
mertinib in patients with T790M-positive NSCLC was
61% and median PFS was 9.6 months [11].
The publication of the FLAURA study, which obtained
a significantly longer PFS and overall survival (OS) than
with standard EGFR-TKI in first-line (18.9 months vs.
10.2 months), led to the approval of osimertinib for
standard first-line treatment.
Osimertinib has been approved in Europe and com-
mercialized in Spain for the treatment of patients with
EGFR T790M-positive (EGFR/T790M+) advanced NSCL
C and in first line regardless the T790M mutation
status.
Then, just after the ASTRIS study had closed recruit-
ment [12], the Foreign Medication Program was opened.
This is a Special Use Medication Program (SUMP) from
the Agencia Española de Medicamentos y Productos
Sanitarios (AEMPS) to access osimertinib in Spain for
the patient population without other treatment options
for pretreated patients with EGFR/T790M+ advanced
NSCLC.
Based on the lack of real-world results in this setting,
and the experience with osimertinib in Spain since 2015,
we proposed a retrospective study to describe the experi-




This was a post-authorization-other-designs, non-
interventional, multicenter, retrospective study that in
no way interfered with physicians’ normal clinical prac-
tice. The study is based on collection of data about those
patients treated with osimertinib within the SUMP and
therefore did not involve any diagnostic or therapeutic
procedures beyond normal clinical practice. The results
provide some insights into the clinical efficacy of osimer-
tinib treatment and consumption of hospital primary
care resources.
Eligible patients had histologically or cytologically con-
firmed stage IIIb/IV EGFR/T790M+ NSCLC and had re-
ceived osimertinib treatment within the osimertinib
Spanish Special Use Medication Program (SUMP).
Living patients had to have signed and dated an Inde-
pendent Ethics Committee/Institutional Review Board
(IRB/EC)-approved written informed consent form fol-
lowing regulatory and institutional guidelines. This had
to be obtained before the performance of any protocol-
related procedures that were not part of normal care.
Assessment
The primary objective was to estimate PFS to osimerti-
nib. Secondary objectives were to establish osimertinib
toxicity profile, estimate duration of response (DOR),
ORR by RECIST v1.1 and report on the consumption of
hospital and primary care resources.
All clinical efficacy objectives were to be assessed de-
pending on treatment line (first, second, third or further
lines).
Date of progression, type of progression, DOR defined
as time from documentation of tumor response until
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disease progression or death, and ORR by RECIST v1.1
were measured.
Adverse events (AEs) related to osimertinib treatment
received within the SUMP in Spain were filed in a Re-
mote Data Capture system (RDC)/Case Report Form
(CRF). Type and severity of AEs were classified accord-
ing to the NCI CTCAE Version 5.0. The causal relation-
ship to the study drug was determined by the physician
and should be used to assess all AEs. The casual rela-
tionship may be either “related” or “not related”.
Independent ethics committee (IEC) or institutional
review board (IRB)
The study was evaluated by the Ethical Committee of
Hospital Universitario Puerta de Hierro de Majadahonda,
Madrid.
The study was also classified by the Spanish Health
Authority as “EPA-OD” (post-authorization study, other
designs). The ethical committees of other hospitals also
reviewed the study as per local practice. The study was
carried out following the Declaration of Helsinki on
Good Clinical Practices and Organic Law 3/2018, 5th
December on Protection of Personal Data and digital
rights that were guaranteed during the study. The study
was coordinated and monitored by the Spanish Lung
Cancer Group (SLCG) and financed by AstraZeneca fol-
lowing the specifications in the protocol. This funding
included the cost of submitting the study for approval to
an accredited IEC; submission for classification to the
AEMPS; database design, maintenance and management;
monitoring activities; statistical analysis and correspond-
ing statistical report.
Data quality assurance
The application used for data collection had safety mar-
gins and internal coherence rules to avoid input of in-
correct data or anomalous or incoherent values. Data
quality and queries were revised and dealt with by the
SLCG Data Management Department. All patient infor-
mation required was included in a Remote Data Capture
system (RDC)/Case Report Form (CRF).
Statistical analysis
A total of approximately 156 patients were included
from several Spanish sites. The observation period was
from August 2016 and December 2018.
The following descriptive statistics were used. Fre-
quency statistics for categorical variables: number and
percentage. Mean, standard deviation, median (inter-
quartile range) and categorical distribution for quantita-
tive variables (e.g. number of exacerbations, hospital
admissions, emergency unit visits, prescriptions, primary
care visits). In addition, two-sided 95% confidence
intervals (CI) were presented for the specified study
outcomes.
PFS was defined from initiation of osimertinib treat-
ment until radiological and/or clinical progression or
death from any cause, whichever occurred first. OS was
defined from initiation of osimertinib to death from any
cause.
Progression was ideally measured by RECIST v 1.1; pa-
tients with unknown progression status at time of data
collection were censored at the date they were last
known to be free of radiological and/or clinical progres-
sion. DOR was defined as time from documentation of
tumor response to disease progression or death.
PFS and DOR were estimated using Kaplan–Meier
analysis.
ORR, defined as percentage of patients achieving
complete or partial response, was evaluated based on
RECIST v 1.1 response criteria.
Clinical efficacy variables were assessed for patients
(squamous vs non-squamous) depending on whether
they received first, second, third or subsequent lines of
treatment. Safety of osimertinib administration was de-
scribed by tabulation of the CTCAE version 5.0. No in-
ferential analyses were foreseen. No interim analyses
were predefined. All study results were considered ex-
ploratory and descriptive by design. All statistical ana-
lyses were performed using R software.
Protocol deviations
There were no major protocol deviations as this was not
a clinical trial and data collection was carried out in a
timely manner and according to protocol. One hundred
and fifty-six patients were included but only 155 were
valid since 1 patient was an inclusion error.
Results
Patient characteristics
One hundred and fifty-five patients who started osimer-
tinib treatment between August 2016 and December
2018 were analyzed. Table 1 shows the main demo-
graphic data. One hundred and fifty-five were T790M
positive: 70% (109/155) had EGFR deletion in exon 19,
25% (39/155) exon 21, and 5% (7/155) other previous
mutation status. Four patients (2.6%) received osimerti-
nib as first line, 83 (53.5%) as second line, 31 (20.0%) as
third line and 37 (23.9%) as the fourth of further lines.
Palliative radiotherapy use was also registered. Of the
155 patients included, 73 (47.1%) received radiotherapy
treatment during follow up, of whom 60 (38.7%) started
radiotherapy before beginning osimertinib treatment,
and 13 (8.4%) started radiotherapy after beginning osi-
mertinib treatment.
Regarding chemotherapy, 152 of the 155 patients in-
cluded (98.1%) received chemotherapy during follow up.
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Efficacy results
According to RECIST v 1.1, best response to osimertinib
was distributed thus: 2 (1.3%) patients with complete re-
sponse (CR), 63 (40.6%) with partial response (PR), 48
(31%) with stable disease (SD), 18 (11.6%) with progres-
sion and 24 (15.5%) without registered response. Of the
131 patients with registered response to osimertinib
treatment, estimated objective response (PR or CR
reached) was 42%. Regarding comparison of response
rates between treatment lines when osimertinib was ad-
ministered, no statistically significant differences were
observed among the 75 patients who received osimerti-
nib in first or second line with registered response (of
the 35 that responded, 46.7%) and the 56 patients who
received osimertinib in third or fourth line with regis-
tered response (of the 30 that responded, 53.6%) (p-
value = 0.482). Table 2 shows the drugs administered as
first, second and third lines prior to osimertinib.
Adverse events (AEs)
Table 3 shows a summary of AEs on osimertinib classi-
fied according to the CTCAEv5.0. One hundred and
fifty-five patients received treatment and were included
in the study. Of these, 76 (49.0%) did not show AEs; 29
(18.7%) showed AEs with a maximum grade of 1; 32
(20.6%) showed AEs with a maximum grade of 2; 14
(9%) showed AEs with a maximum grade of 3; 2 (1.3%)
with a maximum grade of 4; and 2 (1.3%) with a max-
imum grade of 5.
Osimertinib dose was adjusted in 26 patients (16%)
and was due to toxicity in 18 of these (11.6%). Treat-
ment was discontinued in 4 patients (2.6% of the total
treated) due to toxicity.
Follow up and survival
Patients were monitored from the beginning of osimerti-
nib treatment until time of death, loss to follow up or
study closure while they were still alive. Median follow
up for all patients was 11.7 months (range 0.4–32.0
months), while the median for those patients that were
alive was 14.9 months (range 1.8–32.0 months).
Of the 155 patients included, 80 (51.6%) died during
follow up. Estimated median OS for these patients was
17.3 months (95% CI, 13.4–21.3 months). Figure 1.
Overall survival can be compared depending on the
line of treatment patients received. Of the 87 patients
who received osimertinib as first (4 patients) or second
line (83 patients), 46 died during follow up (52.9%).
Of the 68 patients that received osimertinib as third
(31 patients), forth (22 patients), fifth (11 patients),
sixth (2 patients) or seventh line (2 patients), 34 died
during follow up (50.0%). No statistically significant
differences are observed between the overall survival







Mean (SD) 66.9 (11.4)






Non-smoker (≤100 cigarettes over lifetime) 99 (63.9%)
Former smoker (≥1 year) 41 (26.5%)
Smoker 14 (9.0%)















Extra-thoracic adenopathy 16 (10.3%)
Thoracic adenopathy 40 (25.8%)
Meningeal carcinomatosis 2 (1.3%)
Pericardial effusion 7 (4.5%)
Pleural effusion 46 (29.7%)
Liver 19 (12.3%)
Bones 59 (38.1%)
Bilateral lymphangitis 7 (4.5%)
Pleural nodes 29 (18.7%)
Peritoneal 4 (2.6%)
Lung 79 (51.0%)
Central nervous system 22 (14.2%)
Subcutaneous 1 (0.6%)
Suprarenal 9 (5.8%)
Soft tissue 2 (1.3%)
Choroids 2 (1.3%)
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curves of these two groups of patients (osimertinib as
<2nd line versus >3rd line, p-value = 0.392).
Of the 155 patients included, 89 (57.4%) progressed
during follow up, 16 (10.3%) died before progression and
50 (32.3%) were still alive without progression at the tri-
al’s closure. Figure 2 shows the estimated median PFS
curve for this type of patients, with a median PFS of 9.4
months (95% CI, 7.3–11.6 months).
PFS can be compared by treatment line. Of the 87 pa-
tients that received osimertinib as first or second line, 61
progressed or died during follow up (70.1%). Of the 68
patients who received osimertinib as third or further
line, 44 progressed or died during follow up (64.7%). No
statistically significant differences were observed between
the PFS curves of both groups of patients (p-value =
0.113).
Table 2 Drugs administered as first, second and third line prior
to osimertinib
N %










Combination (2 drugs) 27 17.9%
Cisplatin + Pemetrexed 7 4.6%
Cisplatin + Vinorelbine 6 4.0%
Carboplatin + Pemetrexed 5 3.3%
Bevacizumab + Erlotinib 2 1.3%
Carboplatin + Vinorelbine 2 1.3%
Gefitinib + Olaparib 2 1.3%
Carboplatin + Paclitaxel 1 0.7%
Cisplatin + Docetaxel 1 0.7%
Cisplatin + Etoposide VP16 1 0.7%
Combination (3 drugs) 4 2.6%
Bevacizumab + Carboplatin + Paclitaxel 2 1.3%
Bevacizumab + Cisplatin + Pemetrexed 2 1.3%










Combination (2 drugs) 21 30.9%
Carboplatin + Pemetrexed 9 13.2%
Cisplatin + Pemetrexed 7 10.3%
Bevacizumab + Erlotinib 1 1.5%
Carboplatin + Etoposide VP16 1 1.5%
Carboplatin + Paclitaxel 1 1.5%
Gefitinib + Olaparib 1 1.5%
Gefitinib + Pemetrexed 1 1.5%
Table 2 Drugs administered as first, second and third line prior
to osimertinib (Continued)
N %
Combination (3 drugs) 6 8.8%
Bevacizumab + Carboplatin + Paclitaxel* 4 5.9%
Bevacizumab + Cisplatin + Pemetrexed 1 1.5%
Carboplatin + Erlotinib + Pemetrexed 1 1.5%
Combination (4 drugs) 1 1.5%
Atezolizumab + Bevacizumab + Carboplatin +
Paclitaxel**
1 1.5%











Combination (2 drugs) 12 32.4%
Carboplatin + Pemetrexed 6 16.2%
Docetaxel + Nintedanib 2 5.4%
Afatinib + Cetuximab 1 2.7%
Carboplatin + Paclitaxel 1 2.7%
Cisplatin + Pemetrexed 1 2.7%
Gemcitabine + Paclitaxel 1 2.7%
Combination (3 drugs) 2 5.4%
Atezolizumab + Carboplatin + Paclitaxel 1 2.7%
Carboplatin + Erlotinib + Pemetrexed 1 2.7%
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Table 3 Adverse events on treatment with osimertinib
Total 1 2 3 4 5
Patient 155
(100%)
– – – – –
Without adverse events 76 (49.0%) – – – – –
With adverse events 79 (51.0%) 29 32 14 2 2
1. Blood and lymphatic system disorders Anemia 4 (2.6%) 2 2 0 0 0
2. Cardiac disorders Chest pain - cardiac 1 (0.6%) 1 0 0 0 0
Heart failure 1 (0.6%) 0 0 1 0 0
Sinus bradycardia 1 (0.6%) 1 0 0 0 0
3. Congenital, familial and genetic disorders Congenital, familial and genetic disorders - Other, specify 1 (0.6%) 0 1 0 0 0
4. Ear and labyrinth disorders Hearing impaired 1 (0.6%) 0 1 0 0 0
5. Endocrine disorders Cushingoid 1 (0.6%) 1 0 0 0 0
6. Eye disorders Dry eye 2 (1.3%) 2 0 0 0 0
Extraocular muscle paresis 1 (0.6%) 0 1 0 0 0
Eye disorders - other, specify 1 (0.6%) 0 1 0 0 0
Keratitis 1 (0.6%) 1 0 0 0 0
Watering eyes 1 (0.6%) 1 0 0 0 0
7. Gastrointestinal disorders Abdominal pain 1 (0.6%) 1 0 0 0 0
Colitis 1 (0.6%) 0 1 0 0 0
Diarrhea 24 (15.5%) 16 8 0 0 0
Dry mouth 1 (0.6%) 1 0 0 0 0
Gastrointestinal disorders - other, specify 4 (2.6%) 1 2 1 0 0
Gingival pain 1 (0.6%) 0 0 1 0 0
Mucositis oral 10 (6.5%) 6 3 1 0 0
Nausea 9 (5.8%) 6 2 1 0 0
Vomiting 5 (3.2%) 4 1 0 0 0
8. General disorders and administration site
conditions
Edema limbs 1 (0.6%) 1 0 0 0 0
Fatigue 16 (10.3%) 10 2 4 0 0
General disorders and administration site conditions - other,
specify
1 (0.6%) 0 1 0 0 0
Pain 1 (0.6%) 1 0 0 0 0
11. Infections and infestations Conjunctivitis 2 (1.3%) 1 1 0 0 0
Eye infection 1 (0.6%) 0 1 0 0 0
Fungemia 1 (0.6%) 0 1 0 0 0
Joint infection 1 (0.6%) 0 0 1 0 0
Nail infection 1 (0.6%) 1 0 0 0 0
Paronychia 6 (3.9%) 4 1 1 0 0
Rash pustular 2 (1.3%) 0 2 0 0 0
13. Investigations Lipase increased 1 (0.6%) 0 0 1 0 0
Lymphocyte count decreased 1 (0.6%) 0 0 1 0 0
Neutrophil count decreased 3 (1.9%) 0 3 0 0 0
Platelet count decreased 8 (5.2%) 3 4 0 0 1
Serum amylase increased 1 (0.6%) 1 0 0 0 0
White blood cell decreased 1 (0.6%) 0 1 0 0 0
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Follow up of patients with CNS metastases at osimertinib
treatment initiation
Presence of CNS metastases was registered at the begin-
ning of osimertinib treatment in 45 patients (29.9%).
Significant differences were observed according to
the absence or presence of brain metastases prior osi-
mertinib initiation [10.3 months (95% CI, 7.8–12.8
months) and 7.2 months (95% CI, 3.9–10.6 months),
respectively (HR = 1.546 with 95% CI, 1.030–2.321); p-
value = 0.034].
No significant differences were observed when
comparing OS according to presence or absence of
CNS metastases at the initiation of osimertinib treat-
ment (p-value = 0.365). Median OS was 18.3 months
(95% CI, 14.9–21.7 months) and 13.8 months (95%
CI, 11.0–16.6 months) for those patients without and
with brain involvement prior to osimertinib initiation,
respectively.
Follow up of patients that received osimertinib as last
treatment
Overall survival for the 134 patients that received osi-
mertinib as last treatment (no posterior treatment regis-
tered) was compared with that of the 21 patients that
received subsequent chemotherapy and no significant
differences were observed (p-value = 0.411).
Of the 134 patients, whose last treatment was osimer-
tinib, the end date was not registered for 52 of them, so
they continued on treatment at the date of treatment
data collection closure (31/12/2018).
Follow up of T790M+ “de novo” patients
Overall survival and PFS of the 10 (8.3%) “T790M+ de
novo” patients were analyzed.
The small number of these subgroup of patients does
not lend itself to precise estimates, making it difficult to
detect potential differences. Estimated median OS for
Table 3 Adverse events on treatment with osimertinib (Continued)
Total 1 2 3 4 5
14. Metabolism and nutrition disorders Anorexia 7 (4.5%) 5 0 2 0 0
15. Musculoskeletal and connective tissue disorders Arthralgia 2 (1.3%) 2 0 0 0 0
Back pain 1 (0.6%) 1 0 0 0 0
Bone pain 1 (0.6%) 1 0 0 0 0
Flank pain 1 (0.6%) 1 0 0 0 0
Generalized muscle weakness 1 (0.6%) 1 0 0 0 0
17. Nervous system disorders Cognitive disturbance 1 (0.6%) 0 0 1 0 0
Dizziness 3 (1.9%) 3 0 0 0 0
Dysgeusia 2 (1.3%) 2 0 0 0 0
Headache 1 (0.6%) 1 0 0 0 0
Paresthesia 2 (1.3%) 1 1 0 0 0
19. Psychiatric disorders Agitation 1 (0.6%) 1 0 0 0 0
Anxiety 2 (1.3%) 2 0 0 0 0
Confusion 1 (0.6%) 1 0 0 0 0
22. Respiratory, thoracic and mediastinal disorders Cough 1 (0.6%) 0 1 0 0 0
Dyspnoea 7 (4.5%) 3 2 1 1 0
Pneumonitis 4 (2.6%) 2 0 0 1 1
Respiratory, thoracic and mediastinal disorders - other, specify 2 (1.3%) 1 1 0 0 0
23. Skin and subcutaneous tissue disorders Dry skin 2 (1.3%) 1 1 0 0 0
Nail changes 1 (0.6%) 1 0 0 0 0
Palmar-plantar erythrodysesthesia syndrome 2 (1.3%) 0 1 1 0 0
Pruritus 4 (2.6%) 3 1 0 0 0
Rash acneiform 12 (7.7%) 9 3 0 0 0
Rash maculo-papular 3 (1.9%) 2 1 0 0 0
Skin and subcutaneous tissue disorders - other, specify 11 (7.1%) 7 4 0 0 0
26. Vascular disorders Thromboembolic event 3 (1.9%) 1 1 1 0 0
Vascular disorders - other, specify 1 (0.6%) 0 0 1 0 0
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Fig. 1 Estimated median OS of patients treated with osimertinib
Fig. 2 Estimated median PFS of patients treated with osimertinib
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Table 4 Health service resource use during osimertinib treatment
Sum Main DT Median Minim Maxim
Patients
HOSPITAL CARE health resources (n = 155)
R01: Hospital visits/admissions (number) 1421 9.2 14.0 1 0 73
R02: Visits to the Medical Oncologist (number) 2011 13.0 10.0 11 0 56
R03: Visits to other hospital Physician (number) 478 3.1 5.5 1 0 48
R04: Visits to the Hospital Nurse (number) 560 3.6 6.5 0 0 39
R05: Emergency room visits (without admission) (n.) 143 0.9 1.6 0 0 9
R06: Hospitalization in the emergency room (days) 54 0.3 1.0 0 0 6
R07: Hospitalization in ward (days) 759 4.9 14.6 0 0 133
IMAGING TESTS (n = 155)
R08: Chest x-ray (number) 333 2.1 3.1 1 0 16
R09: CT scan (number) 475 3.1 2.5 3 0 12
R10: Magnetic resonance (number) 113 0.7 1.3 0 0 6
R11: Endobronchial ultrasound (number) 2 0.0 0.2 0 0 2
R12: Esophageal Endoscopic Ultrasound (number) 2 0.0 0.2 0 0 2
R13: Other tests (number) 65 0.4 1.2 0 0 10
OTHER complementary tests (n = 155)
R14: Bone scintigraphy (number) 32 0.2 0.6 0 0 3
R15: Sputum cytology (number) 1 0.0 0.1 0 0 1
R16: Thoracentesis (number) 12 0.1 0.3 0 0 3
R17: Biopsy (number) 64 0.4 1.5 0 0 9
R18: Bronchoscopy (number) 12 0.1 0.4 0 0 4
R19: Mediastinoscopy (number) 0 – – – – –
R20: Mediastinotomy (number) 0 – – – – –
R21: Thoracoscopy (number) 0 – – – – –
R22: Spirometry (number) 5 0.0 0.2 0 0 1
R23: Plethysmography (number) 0 – – – – –
R24: Electrocardiogram (number) 198 1.3 3.6 0 0 30
R25: Other tests (number) 18 0.1 0.4 0 0 4
PRIMARY CARE health resources (n = 152)
R26: Visits to primary care (number) 271 1.8 5.4 0 0 39
R27: Visits to primary care Physician (number) 257 1.7 5.0 0 0 36
R28: Visits to primary care Nurse (number) 166 1.1 5.1 0 0 37
R29: Tests performed (number) 112 0.7 4.8 0 0 50
R30: Chest x-ray (number) 20 0.1 0.9 0 0 10
R31: Complete blood count (number) 224 1.5 6.0 0 0 50
R32: Other tests (number) 6 0.0 0.3 0 0 3
LABORATORY TESTS (n = 155)
R33: Immunohistochemistry (number) 35 0.2 1.3 0 0 15
R34: Molecular tests (EGFR, ALK, ROS1, BRAF) (num.) 66 0.4 1.0 0 0 5
R35: Complete blood count (number) 1.873 12.1 10.5 9 0 62
R36: Blood chemistry (number) 1.859 12.0 10.4 9 0 62
R37: Proteins in urine (number) 310 2.0 6.3 0 0 35
R38: Other tests (number) 119 0.8 3.2 0 0 29
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these patients was 14.8 months (95% CI, 3.1–26.5
months), while estimated median PFS was 8.6 months
(95% CI, 0.0–18.1 months).
Of the 6 patients included in this group that had re-
ceived previous treatment, 3 (50%) died during follow
up. Estimated median OS for these patients was 15.6
months, while estimated median PFS was 9.4 months.
Health service resources
Data on use of health service resources during treatment
with osimertinib (from first dose to last) was collected. It
was assumed that all 155 patients had finished treatment
with osimertinib, so none were censored.
The use of health service resources is described ac-
cording to previous characteristics before osimertinib
treatment. Table 4 shows the main number of resources
used according to different characteristics. A comparison
between the values observed using the Mann-Whitney U
test is also shown. The results show that stage T3-T4
patients consumed more resources, with a significant
difference in R13 (other imaging tests). Similarly, non-
smokers and those who had more previous chemother-
apy lines also required more resources.
Discussion
Obtaining real-life data is a very important factor in un-
derstanding drug efficacy. Typically, clinical trials in-
clude a highly selected population that is not always
representative of real-world clinical practice. Our study
consolidates information about the efficacy of osimerti-
nib in any line of treatment, thus over 40% of our
patients received the drug beyond third line, and in 78%
of cases patients had some type of comorbidity.
In fact, PFS was 9.4 months (95% CI, 7.5–11.6), which
does not show significant differences even in fourth line,
according to the literature [13].
It should be remembered that standard treatment with
chemotherapy in these patients does not reach more
than 5–6 months PFS, at best [14]. Other real-world
studies with osimertinib [15] have reached PFS of 10.1
months (95% CI, 9.2–11.0 months), including a recently
published pooled analysis [16] with median PFS of 9.9
months (95% CI, 9.5–12.3), very similar to our own.
Similarly, for the other objective measure of efficacy,
ORR, significant differences were not observed by treat-
ment line. Our study obtained ORR of 50%, very similar
to other retrospective studies [17] and to pivotal studies
with osimertinib in these patients, bearing in mind they
are mostly Caucasian, and Asian populations have higher
response rates and, usually, longer PFS [18].
As well as efficacy, one of the most important factors
is the excellent tolerance and minimal side effects with
osimertinib. Of 155 patients that received treatment and
were included in the study, 76 (49.0%) did not experi-
ence AEs. Only 2 (1.3%) had AEs with a maximum grade
of 4, 2 patients (1.3%) had AEs with a maximum grade
of 5, and discontinuation due to toxicity was just 2.6%,
in line with the pivotal clinical trials published.
CNS involvement, both at time of initial diagnosis and
at disease progression, is common in these patients [19]
and is an indicator of poor prognosis. It should be noted
that among patients with brain metastases at the start of
osimertinib treatment, the majority had been previously
Table 4 Health service resource use during osimertinib treatment (Continued)
Sum Main DT Median Minim Maxim
SURGERIES (n = 155)
R39: Pneumectomy (number) 0 – – – – –
R40: Lobectomy (number) 0 – – – – –
R41: Segmentation or wedge resection (number) 0 – – – – –
R42: Sleeve resection (number) 0 – – – – –
R43: Others (number) 5 0.0 0.2 0 0 2
OTHER RESOURCES/SUPPORT (n = 155)
R44: Radiofrequency ablation (number) 1 0.0 0.1 0 0 1
R45: Radiotherapy palliative (number of sessions) 159 1.0 4.0 0 0 40
R46: Pleurodesis (number) 1 0.0 0.1 0 0 1
R47: Corticosteroids no 117 75.5% yes 38 24.5%
R48: Bisphosphonates no 142 91.6% yes 13 8.4%
R49: Stimulants of erythropoietin no 151 97.4% yes 4 2.6%
R50: Blood transfusions no 147 94.8% yes 8 5.2%
R51: Enteral nutrition no 153 98.7% yes 2 1.3%
R52: Others no 145 93.5% yes 10 6.5%
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treated (58%) and, despite this, response rate with osi-
mertinib was 40%—rising to almost 70% if we include
stabilizations—confirming the drug’s activity in this set-
ting [8]. Notably, all this was achieved outside the frame-
work of a clinical trial in which only asymptomatic
patients with stable disease and not requiring steroids
were included in the previous 4 weeks [20].
Since the publication of the results of the FLAURA
study, which demonstrated clearly improved median PFS
in patients treated with osimertinib (18.9 months) versus
first-generation TKIs (10.2 months) [21], it seems that
the debate about the role of osimertinib now no longer
focuses on its activity in second lines, when the patient
develops the resistance mutation, but on the treatment
sequence.
It is important to note that the greatest use of re-
sources occurs when more lines of treatment have been
given prior to osimertinib. Therefore, in addition to the
clear benefit of early-line osimertinib, toxicity is reduced
and the economic benefit is increased.
Conclusion
Given all of the above, we believe that it is important to
report real-world data from patients treated with osi-
mertinib in any line. Our results with 155 patients are
similar to those of real-world studies in China with 77
patients [22], Germany with 51 [15], or France with 205
patients [23] and demonstrate that real-world data
closely agrees with that obtained in pivotal clinical trials,
even without patient selection.
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